MX2019014875A - Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. - Google Patents

Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.

Info

Publication number
MX2019014875A
MX2019014875A MX2019014875A MX2019014875A MX2019014875A MX 2019014875 A MX2019014875 A MX 2019014875A MX 2019014875 A MX2019014875 A MX 2019014875A MX 2019014875 A MX2019014875 A MX 2019014875A MX 2019014875 A MX2019014875 A MX 2019014875A
Authority
MX
Mexico
Prior art keywords
rasopathies
compounds
inflammatory diseases
fibrotic disease
cancers
Prior art date
Application number
MX2019014875A
Other languages
English (en)
Inventor
Yaron R Hadari
Luca Carta
Michael Schmertzler
Theresa M Williams
Charles H Reynolds
Rebecca Hutcheson
Original Assignee
SHY Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHY Therapeutics LLC filed Critical SHY Therapeutics LLC
Publication of MX2019014875A publication Critical patent/MX2019014875A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)

Abstract

En la presente memoria se proporcionan métodos y composiciones para tratar cánceres, enfermedades inflamatorias, rasopatías y enfermedad fibrótica que implican la señalización aberrante de Ia superfamilia Ras a través de la unión de compuestos al dominio de unión a GTP de proteínas de Ia superfamilia Ras que incluyen, en ciertos casos, K-Ras y mutantes de esta, y un nuevo método para someter a ensayo dichas composiciones.
MX2019014875A 2017-06-21 2018-06-20 Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. MX2019014875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523114P 2017-06-21 2017-06-21
PCT/US2018/038613 WO2018237084A1 (en) 2017-06-21 2018-06-20 COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES

Publications (1)

Publication Number Publication Date
MX2019014875A true MX2019014875A (es) 2021-01-29

Family

ID=62904595

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019014875A MX2019014875A (es) 2017-06-21 2018-06-20 Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2022010225A MX2022010225A (es) 2017-06-21 2019-12-10 Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2022010224A MX2022010224A (es) 2017-06-21 2019-12-10 Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022010225A MX2022010225A (es) 2017-06-21 2019-12-10 Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2022010224A MX2022010224A (es) 2017-06-21 2019-12-10 Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.

Country Status (14)

Country Link
US (9) US10588894B2 (es)
EP (2) EP4331679A3 (es)
JP (3) JP7514005B2 (es)
KR (1) KR102736865B1 (es)
CN (1) CN111032662B (es)
AU (2) AU2018288841B2 (es)
BR (1) BR112019027640A2 (es)
CA (1) CA3066939A1 (es)
EA (1) EA201992780A1 (es)
IL (2) IL271230B2 (es)
MA (1) MA49458A (es)
MX (3) MX2019014875A (es)
SG (1) SG11201911929XA (es)
WO (1) WO2018237084A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
KR20210039368A (ko) * 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
EP3861000A1 (en) 2018-10-01 2021-08-11 Genzyme Corporation Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
MX2021003904A (es) 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN113396149B (zh) 2018-12-06 2024-07-02 星座制药公司 Trex1的调节剂
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020159942A1 (en) * 2019-01-29 2020-08-06 Tosk, Inc. Pyrazolopyrimidine modulators of ras gtpase
EP3929185A4 (en) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NITROGEN CONDENSED CYCLIC COMPOUND, METHOD OF PRODUCTION THEREOF AND USE THEREOF
WO2020214537A1 (en) 2019-04-15 2020-10-22 Tosk, Inc. Modulators of ras gtpase
CA3137193A1 (en) * 2019-04-24 2020-10-29 The Governors Of The University Of Alberta Non-peptidic heterocycle-containing compounds for the treatment of alzheimer's disease
JP7502337B2 (ja) * 2019-05-20 2024-06-18 カリフォルニア インスティチュート オブ テクノロジー Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
US12421236B2 (en) 2019-06-25 2025-09-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
US20220288033A1 (en) * 2019-09-04 2022-09-15 Agency For Science, Technology And Research Heterocyclic compounds as modulators of beta-catenin / tcf4 interaction
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4072547A1 (en) * 2019-12-13 2022-10-19 Institut National De La Sante Et De La Recherche Medicale - Inserm Epac1 inhibitors for the treatment of idiopathic pulmonary fibrosis
CA3167268A1 (en) * 2020-03-27 2021-09-30 Ioannis PAPASOTIRIOU Nucleotide analogues for the treatment of coronaviruses
KR20230005210A (ko) * 2020-04-08 2023-01-09 레믹스 테라퓨틱스 인크. 스플라이싱을 조절하기 위한 화합물 및 방법
KR20230007441A (ko) * 2020-04-28 2023-01-12 글로벌 블러드 테라퓨틱스, 인크. 페로포르틴 억제제로서의 시클로알킬 피리미딘
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2021228734A1 (en) * 2020-05-12 2021-11-18 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds
KR20230017217A (ko) * 2020-05-27 2023-02-03 콘스텔레이션 파마슈티칼스, 인크. Trex1의 조절제로서의 치환된 벤즈아마이드
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN111996251B (zh) * 2020-06-19 2024-03-26 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种恶性胶质瘤生物标志物的应用
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
US12180220B2 (en) 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
CN116723845A (zh) * 2020-11-02 2023-09-08 特雷西拉公司 脱氧胞苷激酶抑制剂的结晶形式及其用途
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US20240124483A1 (en) * 2021-01-27 2024-04-18 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
KR20230146054A (ko) * 2021-02-12 2023-10-18 더 스크립스 리서치 인스티튜트 재생 장기 수복을 위한 yap 전사 활성의 소분자 활성제들
US20240158386A1 (en) * 2021-03-02 2024-05-16 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
CN117136189A (zh) * 2021-04-09 2023-11-28 先声再明医药有限公司 泛素特异性蛋白酶1（usp1）抑制剂
CN114452286A (zh) * 2021-07-23 2022-05-10 上海交通大学医学院附属新华医院 Ral抑制剂防治骨关节炎
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
IL312642A (en) 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430041A4 (en) * 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
PL4514782T3 (pl) 2022-05-19 2026-02-23 Astrazeneca Ab Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby
CN114959012B (zh) * 2022-05-30 2023-04-07 北京医院 用于检测肌腱损伤的产品
CN115043851B (zh) * 2022-08-15 2023-01-06 山东第一医科大学第一附属医院(山东省千佛山医院) 一种噻吩[2,3-d]嘧啶类杂环化合物及其制备方法和应用
EP4342467A1 (en) * 2022-09-20 2024-03-27 Masarykova Univerzita Ku inhibitors for use in tumor therapy
ES3022546T3 (en) * 2023-02-24 2025-05-28 Univ Santiago Compostela Small molecules targeting glycoprotein vi as antiplatelet agents for use in the prevention and/or treatment of thrombosis and associated pathologies
CN117551057B (zh) * 2023-03-24 2026-04-10 浙江海正药业股份有限公司 苯并环类衍生物及其制备方法和用途
WO2025017207A1 (en) * 2023-07-20 2025-01-23 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Inhibitors of smndc1 and their therapeutic use
CN117126072B (zh) * 2023-08-24 2025-12-30 中国药科大学 一种含酯链pd-1/pd-l1小分子抑制剂及其制备方法和应用
CN117298277A (zh) * 2023-10-05 2023-12-29 东南大学 Dexras1抑制剂及其应用
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Ｈｐｄ抑制劑組成物及使用方法
WO2025215450A1 (en) * 2024-04-08 2025-10-16 Sk Biopharmaceuticals Co., Ltd. Thiazole compounds as sodium channel blockers
WO2025254394A1 (ko) * 2024-06-05 2025-12-11 연세대학교 산학협력단 Slc1a5 변이체 미토콘드리아 글루타민 수송체의 억제제를 포함하는 항암용 조성물

Family Cites Families (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE295381C (es)
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE1959403A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2050815A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidine
DE2050814A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue Verfahren zur Herstellung von 2-(5-Nitro-2-furyl)-thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidinen
DE1959402A1 (de) 1969-11-26 1971-06-03 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-4-oxi-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2050816A1 (de) 1970-10-16 1972-04-20 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-(Nitro-2-furyl>thieno eckige Klammer auf 3,2-d eckige Klammer zu pyrimidine
DE2039662A1 (de) 1970-08-10 1972-02-17 Thomae Gmbh Dr K Neue 2-(5-Nitro-2-furyl)-vinyl-thieno-[3,2-d]pyrimide
JPS5659778A (en) 1979-10-23 1981-05-23 Showa Denko Kk Dimethylthienopyrimidione derivative
IT1208123B (it) 1983-04-19 1989-06-06 Fondedile Spa Colonna in conglomerato realizzata nel terreno in situ mediante immissione di materiali inerti durante la perforazione e contemporaneao successiva iniezione con opportuni leganti, procedimenti di esecuzione relativi
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0276057B1 (en) 1987-01-21 1994-03-09 Merck & Co. Inc. Piperazinylpyrimidines as beta-adrenergic receptor blocking agents
US5102877A (en) 1989-04-28 1992-04-07 Fujisawa Pharmaceutical Co., Ltd. 1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds
GB8912335D0 (en) 1989-05-30 1989-07-12 Smithkline Beckman Intercredit Compounds
DE3922735A1 (de) 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
DD295381A5 (de) 1990-10-01 1991-10-31 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 8-amino-pyrazolo/4',3':4,5/thieno/3,2-d/pyrimidin-4-onen
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
JP2972843B2 (ja) 1991-04-02 1999-11-08 工業技術院長 有機非線形光学材料
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
TW201311B (es) 1991-06-17 1993-03-01 Hoffmann La Roche
WO1993003040A1 (fr) 1991-08-05 1993-02-18 Taisho Pharmaceutical Co., Ltd. Derive de thienopyrimidin-4-one
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
ATE144500T1 (de) 1992-07-17 1996-11-15 Rohm & Haas 2-substituierte pyrimidine und ihre verwendung als herbizide
WO1994008975A1 (fr) 1992-10-16 1994-04-28 Nippon Soda Co., Ltd. Derive de pyrimidine
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5654037A (en) * 1995-03-24 1997-08-05 Apx International Method of minimizing defects in painted composite material products
US6255310B1 (en) 1996-02-07 2001-07-03 Neurocrine Biosciences Inc. Thiophenopyrimidines
EP0807633B1 (en) 1996-05-15 2002-11-06 Pfizer Inc. Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
DE69717453T2 (de) 1996-06-06 2003-07-10 Otsuka Pharmaceutical Factory, Inc. Amid derivate
DE19632423A1 (de) 1996-08-12 1998-02-19 Merck Patent Gmbh Thienopyrimidine
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
WO1998023620A1 (en) 1996-11-28 1998-06-04 Cheil Jedang Corporation Cathecol derivatives and a method for the preparation thereof and a pharmaceutical composition containing the same
JP2001524121A (ja) 1997-05-08 2001-11-27 アグレボ・ユー・ケイ・リミテツド 殺菌剤
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6323208B1 (en) 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
GB9719411D0 (en) 1997-09-12 1997-11-12 Ciba Geigy Ag New Pesticides
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
CN1346358A (zh) 1999-03-30 2002-04-24 日本曹达株式会社 噻吩并嘧啶化合物及其盐和制备方法
GB9915437D0 (en) 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US7173040B2 (en) * 2000-09-25 2007-02-06 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derinazoline derivatives
CA2423981A1 (en) 2000-09-29 2003-03-28 Kimiko Ichikawa Thienopyrimidine compounds and salts thereof and process for the preparation of the same
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
EP1254903B1 (en) 2001-04-20 2005-06-08 Ciba SC Holding AG 4-Amino-2-(pyridin-2-yl)pyrimidine as microbicidal active substances
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
JPWO2003035653A1 (ja) 2001-10-26 2005-02-10 日本曹達株式会社 ピリドチエノピリミジン化合物およびその塩
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
TW200401770A (en) 2002-06-18 2004-02-01 Sankyo Co Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
WO2004065392A1 (en) 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ES2324536T7 (es) 2003-06-11 2012-03-16 Xention Limited Derivados de tenopirimidina como inhibidores de los canales de potasio.
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
AU2004272437A1 (en) 2003-09-09 2005-03-24 Ono Pharmaceutical Co., Ltd. CRF antagonists and heterobicyclic compounds
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
US20050176738A1 (en) 2003-11-07 2005-08-11 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
WO2005105780A2 (en) 2004-04-28 2005-11-10 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
ZA200609259B (en) 2004-04-30 2008-07-30 Takeda Pharmaceutical Heterocyclic amide compound and use thereof as an mmp-13 inhibitor
US7683097B2 (en) 2004-05-27 2010-03-23 Propharmacon Inc. Topoisomerase inhibitors
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
US7557112B2 (en) 2004-10-08 2009-07-07 Astellas Pharma Inc. Aromatic-ring-fused pyrimidine derivative
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2005323797B2 (en) 2005-01-10 2009-07-09 Pfizer Inc. Pyrrolopyrazoles, potent kinase inhibitors
US20090298856A1 (en) 2005-05-11 2009-12-03 Rebecca Elizabeth Brown 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1)
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
US7816351B2 (en) * 2005-09-23 2010-10-19 Equispharm Co., Ltd 5,6-dimethylthieno[2,3-di] pyrimidine derivatives, the preparation method thereof and the pharmaceutical composition comprising the same for anti-virus
WO2007056214A2 (en) 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
US20070099877A1 (en) 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
US20090170834A1 (en) * 2005-12-22 2009-07-02 Prolexys Pharmaceuticals, Inc. Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
WO2007093365A2 (en) 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
KR100846988B1 (ko) * 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US8173806B2 (en) 2006-03-17 2012-05-08 Mitsubishi Gas Chemical Company, Inc. Method for production of quinazolin-4-one derivative
TW200801012A (en) * 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
AU2007267843B2 (en) 2006-05-25 2011-10-13 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
WO2007146284A2 (en) 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
FR2904318B1 (fr) 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
WO2008020622A1 (en) 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
ZA200901009B (en) 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
CA2660951A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
US20110144140A1 (en) * 2006-09-07 2011-06-16 Eriksen Birgitte L Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
CA2668579A1 (en) 2006-11-06 2008-06-05 Neurogen Corporation Cis-cyclohexyl substituted pyrimidinone derivatives
KR20090087027A (ko) 2006-11-13 2009-08-14 일라이 릴리 앤드 캄파니 염증 질환 및 암의 치료를 위한 티에노피리미디논
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
RU2470936C2 (ru) 2006-12-07 2012-12-27 Дженентек, Инк. Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20090030196A1 (en) 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082840A1 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
WO2008092860A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008092862A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
EP2134716A1 (en) 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7906513B2 (en) 2007-04-26 2011-03-15 Enanta Pharmaceuticals, Inc. Hydrazide-containing hepatitis C serine protease inhibitors
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
WO2009026241A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
WO2009064388A2 (en) 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
WO2009100225A1 (en) 2008-02-07 2009-08-13 Virobay, Inc. Inhibitors of cathepsin b
PE20091653A1 (es) 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso
WO2009121036A2 (en) 2008-03-27 2009-10-01 Neurogen Corporation Substituted aryl pyrimidinone derivatives
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010037765A2 (en) * 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
US20100093702A1 (en) 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8962639B2 (en) 2009-05-29 2015-02-24 Abbvie Inc. Potassium channel modulators
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
MX2012002366A (es) 2009-08-27 2012-03-29 Merck Sharp & Dohme Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
EP2539337A1 (en) * 2010-02-22 2013-01-02 F. Hoffmann-La Roche AG Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
EP2539338A1 (en) 2010-02-24 2013-01-02 Syngenta Participations AG Novel microbicides
WO2012004900A1 (en) 2010-07-09 2012-01-12 Aska Pharmaceutical Co., Ltd. Thienopyrimidine compounds
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2616442B8 (en) 2010-09-14 2018-10-17 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
TW201241005A (en) 2011-02-18 2012-10-16 Alexion Pharma Inc Methods for synthesizing molybdopterin precursor Z derivatives
GB201105659D0 (en) * 2011-04-01 2011-05-18 Xention Ltd Compounds
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
EP2708540B1 (en) 2011-05-10 2018-07-25 Kyowa Hakko Kirin Co., Ltd. Pyrimido-diazepinone compound
PL2710018T3 (pl) 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Związki makrocykliczne jako inhibitory kinaz białkowych
EP2816037A3 (en) 2011-05-24 2015-04-01 Università degli Studi di Bari "Aldo Moro" New 1-arylpiperazinic ligands of 5-HT7 receptor and use thereof
AU2012282076A1 (en) 2011-07-13 2014-02-27 Novartis Ag 4 - piperidinyl compounds for use as tankyrase inhibitors
MX2014002542A (es) * 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
WO2013078126A1 (en) * 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US20150291590A1 (en) 2012-09-17 2015-10-15 Cellixbio Private Limited Compositions and methods for the treatment of metabolic diseases
WO2014045039A2 (en) 2012-09-21 2014-03-27 Cancer Research Technology Limited Identification of protein kinase substrates
KR101446680B1 (ko) 2013-02-08 2014-10-07 한국과학기술연구원 ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
CN105339371A (zh) 2013-03-07 2016-02-17 葛兰素史密斯克莱有限责任公司 作为沉默调节蛋白调节剂的噻吩并[3,2-d]嘧啶-6-甲酰胺和类似物
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
RU2015148359A (ru) 2013-04-12 2017-05-15 Асана Биосайенсис, Ллк Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
US9238034B2 (en) * 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
US9797882B2 (en) * 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
CN105658639A (zh) 2013-08-22 2016-06-08 豪夫迈·罗氏有限公司 炔基醇和应用方法
KR20160060100A (ko) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 치환된 아미노피리미딘 화합물 및 이용 방법
EP3053926B1 (en) 2013-09-30 2018-08-08 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof
US9486448B2 (en) 2013-10-03 2016-11-08 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
JO3805B1 (ar) * 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2015160192A1 (ko) 2014-04-15 2015-10-22 연세대학교 산학협력단 티에노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 백혈병 치료 및 예방용 약학 조성물
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
WO2015169421A1 (en) 2014-05-07 2015-11-12 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
WO2015183989A1 (en) 2014-05-27 2015-12-03 Navigen, Inc. Arf6 inhibitors and methods of synthesis and use thereof
CN104230952B (zh) 2014-08-16 2017-02-01 沈阳药科大学 含有嘧啶骨架的化合物及其制备方法和用途
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
RU2684396C2 (ru) * 2014-10-29 2019-04-09 Донг-А Ст Ко., Лтд. Новые соединения пиридопиримидинона для модулирования каталитической активности гистонлизиндеметилаз (KDMS)
WO2016142312A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
EP3277678B1 (en) 2015-04-03 2020-03-18 NantBio, Inc. Compositions and methods of targeting mutant k-ras
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10421764B2 (en) 2015-04-24 2019-09-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Mutant KRas inhibitors
AU2016260317B2 (en) * 2015-05-13 2021-02-04 Memorial Sloan Kettering Cancer Center Macropinocytosis in cancer
US10463649B2 (en) 2015-06-08 2019-11-05 Texas Tech University System Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors
WO2016201257A2 (en) 2015-06-10 2016-12-15 The Johns Hopkins University Compositions and methods for identifying adp-ribosylated sites by mass spectrometry
WO2017015562A1 (en) 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
JP2018520201A (ja) 2015-07-23 2018-07-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｇｆベーター受容体アンタゴニスト
CA2995830A1 (en) 2015-08-17 2017-02-23 Duquesne University Of The Holy Spirit Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
US20170057955A1 (en) 2015-08-26 2017-03-02 Dong-A Socio Holdings Co., Ltd. Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs)
JP2018528951A (ja) 2015-08-31 2018-10-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ＴＧＦβ受容体アンタゴニスト
WO2017058805A1 (en) * 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) * 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
ES2969565T3 (es) 2015-09-30 2024-12-13 Max Planck Ges Zur Foerderung Derwissenschaften E V Derivados heteroarílicos como inhibidores de la sepiapterina reductasa
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
SG11201804901WA (en) * 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
DK3436463T3 (da) 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
EP3290412A1 (en) 2016-08-31 2018-03-07 Università degli Studi di Siena Hiv-1 nucleocapsid inhibitors
KR102765158B1 (ko) 2016-12-11 2025-02-07 연세대학교 산학협력단 티에노피리미딘 유도체 및 이의 용도
EA201992780A1 (ru) * 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
JP2020524733A (ja) * 2017-06-22 2020-08-20 エクソンモービル リサーチ アンド エンジニアリング カンパニーＥｘｘｏｎ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｅｎｇｉｎｅｅｒｉｎｇ Ｃｏｍｐａｎｙ メチルパラフィン含有炭化水素流体に基づく低粘度潤滑油
US20220117968A1 (en) 2017-07-17 2022-04-21 Saint Louis University Thieno[2,3-d)pyrimidines and benzofuro(3,2-d)pyrimidines as antimicrobial agents
CN107721982B (zh) 2017-10-16 2019-12-03 中山大学 一种抗肥胖症化合物及其制备方法和应用
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
CN111094317B (zh) 2017-12-29 2023-03-31 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib

Also Published As

Publication number Publication date
SG11201911929XA (en) 2020-01-30
EP4331679A3 (en) 2024-04-03
US11000515B2 (en) 2021-05-11
US11213515B1 (en) 2022-01-04
IL310023B1 (en) 2025-08-01
IL310023A (en) 2024-03-01
JP7627054B2 (ja) 2025-02-05
JP2020524703A (ja) 2020-08-20
KR20200041294A (ko) 2020-04-21
EP3642209A1 (en) 2020-04-29
AU2018288841A1 (en) 2020-01-02
AU2022263550A1 (en) 2022-12-08
WO2018237084A1 (en) 2018-12-27
EP3642209B1 (en) 2023-11-29
CN111032662A (zh) 2020-04-17
US10588894B2 (en) 2020-03-17
JP2022177278A (ja) 2022-11-30
US20200061037A1 (en) 2020-02-27
US20230149369A1 (en) 2023-05-18
EA201992780A1 (ru) 2020-06-02
AU2018288841B2 (en) 2022-09-29
US20200054614A1 (en) 2020-02-20
US10940139B2 (en) 2021-03-09
IL310023B2 (en) 2025-12-01
BR112019027640A2 (pt) 2020-07-07
MX2022010225A (es) 2022-09-19
MA49458A (fr) 2020-04-29
JP2023179774A (ja) 2023-12-19
KR102736865B1 (ko) 2024-12-03
CA3066939A1 (en) 2018-12-27
EP4331679A2 (en) 2024-03-06
US10933054B2 (en) 2021-03-02
US20200121660A1 (en) 2020-04-23
US20220347162A1 (en) 2022-11-03
US20190022074A1 (en) 2019-01-24
JP7514005B2 (ja) 2024-07-10
MX2022010224A (es) 2022-11-16
US11541041B1 (en) 2023-01-03
IL271230A (en) 2020-01-30
AU2022263550B2 (en) 2024-07-04
CN111032662B (zh) 2024-10-15
US11026930B1 (en) 2021-06-08
IL271230B2 (en) 2024-06-01
IL271230B1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2022010224A (es) Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12019501635A1 (en) Anti-tgf-beta antibodies and their use
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
PH12021552538A1 (en) Heavy chain antibodies binding to psma
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MD4801B1 (ro) Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice
MX2022015248A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
MY179105A (en) Methods of treating alzheimer's disease
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
PH12018550186A1 (en) Pharmaceutical combinations for treating cancer
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
HK1259083A1 (zh) 用於治疗系统性肥大细胞增多症的方法和组合物
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MA50163A (fr) Compositions, utilisations et méthodes pour le traitement de l'infertilité et de la sous-fertilité